Applying PacBio Long-Read Sequencing for Human Biomedical Research
Long-read sequencing has begun to dramatically change the way that researchers work with genomic information, from studying the complex architecture of a genome, to sequencing whole genomes de novo with increased ease.
On April 28 2016 hosted a webinar in partnership with long-read experts PacBio® exploring how long-read sequencing is currently being applied to research and diagnostics in cancer. PacBio® CSO Jonas Korlach was joined by Adam Ameur from National Genomics Infrastructure in Sweden, and Giancarlo Russo from the Functional Genomics Center, Zurich for a series of presentations and an audience Q&A.
Watch the on demand broadcast now and join the long-read revolution.
On the panel:
“Making SMRT sequencing ready for diagnostic use”
Adam Ameur received his PhD in Bioinformatics from Uppsala University in 2008, and has worked with massively parallel sequencing (MPS) since 2007. At present he is employed at the National Genomics Infrastructure in Sweden, one of the largest MPS sites in Europe. Among other things he works with development and evaluation of new sequencing applications, in particular for clinical use.
“Non-invasive, early detection of colorectal cancer driving mutations: a peek at the future of single molecule sequencing”
As a senior bioinformatician at the Functional Genomics Center Zurich, Giancarlo is involved in all computational workflows pertinent to genomics, transcriptomics and multi-omics data. Prior to joining the FGCZ in December 2011, Giancarlo has received a Ph.D. in Mathematics from Cardiff University (2009) and worked as Associate Researcher at the MRC Centre for Neuropsychiatric Genetics and Genomics (2009-2011) at Cardiff University, School of Medicine.
“Applications of Single Molecule, Real-Time (SMRT) Sequencing in Cancer Research”
Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company’s eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University. In 2013, Dr. Korlach was honored by the White House as an Immigrant Innovator “Champion of Change.” He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.
By registering for this event you agree to being contacted by Front Line Genomics with other news and webinars – you can unsubscribe from these emails. You also agree that the sponsor may contact you afterwards.